Vis enkel innførsel

dc.contributor.authorØverberg, Linda Thøring
dc.contributor.authorLugg, Elise Fritsch
dc.contributor.authorGaarder, Mona
dc.contributor.authorLanghammer, Birgitta
dc.contributor.authorThommessen, Bente
dc.contributor.authorRønning, Ole Morten
dc.contributor.authorMorland, Cecilie
dc.date.accessioned2023-02-14T10:02:10Z
dc.date.available2023-02-14T10:02:10Z
dc.date.created2022-09-21T09:11:55Z
dc.date.issued2022-06-17
dc.identifier.citationHeliyon. 2022, 8 (6), 1-10.en_US
dc.identifier.issn2405-8440
dc.identifier.urihttps://hdl.handle.net/11250/3050618
dc.description.abstractStroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesHeliyon;Volume 8, Issue 6, e09661
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectBiomarkersen_US
dc.subjectDisabilitiesen_US
dc.subjectGrowth factorsen_US
dc.subjectIrisinen_US
dc.subjectIschemic strokeen_US
dc.subjectPlasticityen_US
dc.titlePlasma levels of BDNF and EGF are reduced in acute stroke patientsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 The Author(s)en_US
dc.source.articlenumbere09661en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doihttps://doi.org/10.1016/j.heliyon.2022.e09661
dc.identifier.cristin2053747
dc.source.journalHeliyonen_US
dc.source.volume8en_US
dc.source.issue6en_US
dc.source.pagenumber1-10en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal